Lilly launches Mounjaro (tirzepatide), offers new treatment option for obesity and type 2 diabetes
Express Pharma
MARCH 20, 2025
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. 2021;398(10300):583-598. 2022;327(6):534-545. doi:10.1001/jama.2022.0078 Obesity, sleep apnea, and hypertension. Hypertension.
Let's personalize your content